Say hello to EMLy Co-pilot, the AI biologics discovery platform built on an extensive immune database
- Michelle Teng and Jacob Hurst
- 2 days ago
- 3 min read
Imagine discovering new biologics not in weeks, but in minutes...
Today, British techbio pioneer Etcembly opens early access for EMLy Co-pilot
Researchers can use the chat-based AI platform for conversations that tap into the real-life immune secrets of cancer survivors
EMLy Co-pilot accelerates time to candidate selection and boosts the odds of clinical success
OXFORD, UK.
Start smarter, discover faster
EMLy Co-pilot’s unique intelligence is rooted in a proprietary immune dataset of human health and disease, EMLy, an extensive library built from Etcembly’s landmark long-term survivor study. Within this unparalleled dataset lie the real-life immunological secrets of resistance, adaptation, and survival. Using a simple chat interface, EMLy Co-pilot translates the data to rapidly design, optimise and troubleshoot viable biologic candidates ready for wet-lab validation.
Bound only by curiosity
“Historically, developing antibody and TCR-based therapeutics required large specialist teams, and years of painstaking work”, says Michelle Teng, Etcembly co-founder and CEO. Now, for the first time, scientists everywhere can explore bold ideas with minimal cost and commitment, tapping into this library to explore new therapies at unprecedented speed. EMLy Co-pilot’s unique intelligence helps scientists to de-risk early exploration, identify liabilities earlier in the process, and avoid costly downstream failures particularly around developability.
Discovery at the speed of imagination
EMLy Co-pilot condenses time-consuming, complex workflows into minutes of intuitive interactions. It has already more than halved discovery timelines and is set to accelerate them further. Etcembly used it to deliver a high-affinity T cell engager in just six months outperforming the industry’s two-year norm. It enables faster innovation, reduces the pain points in early-stage discovery, and maximises the chance of clinical success.
As Jake Hurst, Etcembly co-founder and CTO explains, “with accuracy and reproducibility where you need it and creativity where you want it, the only boundaries remaining are curiosity and imagination.”
EMLy Co-pilot opens up the field of play. Through chatting to EMLy, a suite of models and computational tools is now accessible to all, from nimble biotechs exploring novel biological targets, to global pharmaceutical leaders optimising their next blockbuster candidate. Now anyone can explore “what-ifs” with the user-friendly interface that feels more like speaking to a lab partner than using a machine.
The platform launches with two access models:
Expert: Unlimited annual access
Enterprise: Integrated custom solutions
With EMLy Co-pilot, discovery is about people: the patients waiting, the survivors who inspire, the innovators who dare. Every biologic begins with a story. Now, every lab gets to write one.
Start smarter. Discover faster.
---- END ---
About Etcembly
Founded in 2020, Etcembly fuses human brilliance with the precision of artificial intelligence to accelerate the next generation of immunotherapy. Its flagship platform, EMLy Co-pilot, combines advanced immune engineering AI with the largest known immune dataset, Etcembly’s pioneering ‘long-term survivor study’. By compressing time-consuming protein engineering workflows into minutes of guided interaction, Etcembly empowers scientists everywhere, to start smarter and design novel immunotherapies at the speed of imagination. www.etcembly.io
About the Long-Term Survivor Study
Etcembly invites people who are living with or have survived cancer, as well as healthy volunteers, to participate in a research study to build a deeper understanding of T-cell receptors and antibodies that may drive the immune response to cancer. Uncovering these specific targets will allow discovery teams using EMLy Co-pilot to leverage the scientific understanding of these targets, to help develop effective treatments for the cancer survivors of the future. www.etcembly.io/long-term-survivor-study